My fiancé got my engagement ring here and it’s absolutely beautiful. I wanted something a little different and what he received from them was just perfect. My main request was it to be rose gold and sparkly and it definitely fits that bill. The customer service is great and they were very willing to resize my ring when I wanted it a little tighter. We will both be getting our wedding bands here and I can’t wait to see how they turn out !
When my fiance put the engagement ring on my hand, I cried. We were promising a life together full of love and adventure. I could not have picked out a better setting than my fiance did. I absolutely love my ring and I am still blown away by its beauty. We cannot wait to come back to CDI Diamonds & Jewelry to pick out our wedding bands! Thank you all so much for guiding my fiance through the process and helping him pick out the perfect ring!
My fiancé purchased my engagement ring and wedding band from CDI diamonds & jewelry, I can't fathom any jewelry store doing a better job. They were not only consistent with getting back to me on my concerns in a timely manner, they made sure that I received the ring of my dreams, the exact way I dreamt it. In other words, "dreams come true at CDI DIAMONDS & JEWELRY." I could go on and on about their professionalism, promptness, humanly kindness, consideration and amazing prices. Trade in your gold, reuse your gems, get a diamond & save thousands of dollars – it’s all possible at Scott’s! Whether you’ve inherited jewelry from your grandmother that you want to re-purpose into your engagement ring, or it’s just time to redo your wedding ring, we can help. Just another way to save you money – and the planet. And if you’re starting from scratch, we can get any certified diamond or gemstone you desire – even the gorgeous, very affordable, lab grown diamonds! Don’t worry – we’ve got literally thousands of unique, custom jewelry designs to inspire you! Contact us today and let’s create something beautiful, together! [Todd Harrison is the CIO and co-founder of CB1 Capitaland a columnist for Investopedia. The views expressed herein are those of the author and do not necessarily reflect the views of Investopedia.] In recent weeks, Tilray Inc. (TLRY) became the first Canadian licensed produced to list on the NASDAQ, while Constellation Brands (STZ) invested an additional $5 billion-dollars in Canopy Growth Corporation (CGC) to develop cannabis-infused beverages. What both companies have in common is that inherent in their respective share prices, investors are getting the upside call option of their biotech research & development. While history paints a picture of Reefer Madness, cannabis and hemp have emerged as the base-line ingredients in a wide array of end-products and use cases that include building materials, plastic composites, cosmetics & vanity, pet supplements, clothing, food, and yes, medicine. While each of these verticals have investment merits, it is the wellness arena that excites us most. Because the medical community informs the stock market much of it hasn’t studied the science behind the endocannabinoid system. Most doctors remain unaware the cannabinoids found in cannabis are identical in action to the endocannabinoids our bodies produce to regulate neurotransmissions. By using our endocannabinoid system (ECS) as a retrograde pathway, we are able to target a multitude of pernicious conditions and disease. Most of the world is just beginning to understand the therapeutic benefits of cannabis but two players on the global stage figured it out long ago. Israel has studied the science for 50 years, thanks to groundbreaking work of Dr. Raphael Mechoulam, but there are only a handful of publicly traded early-stage biotech companies with which to express an investment view. And there’s the UK-based GW Pharmaceuticals (GWPH). governments commissioned separate but similar studies to help determine whether cannabis had the potential for medical efficacy, and both found there to be encouraging evidence. ignored those findings and continued its failed War on Drugs, while the U.K. government laid the groundwork for GW Pharmaceuticals, which was founded in 1998.
Over the last twenty years, GW has conducted groundbreaking clinical research and importantly, they’ve filed numerous patents in both the U.S. They’ve studied CBD, THC, and a wide range of novel cannabinoid molecules in several distinct therapeutic areas, including epilepsy, autism, cancer and schizophrenia. In short, they’ve got a massive first-mover advantage in a space that most people still don’t realize is a space. Of course, there is much to learn once the Federal decriminalization of cannabis arrives, paving the way for research, banking and institutional investment in US-based operators, along with what I presume will be a fair amount of M&A. There are two pathways on that front: legislatively, through efforts such as the STATES ACT; and with the demonstration of medical efficacy, which compels the DEA to reschedule within 90 days. GW’s first drug, Epidiolex ™ for the treatment of childhood onset epilepsy disorders, received FDA approval in June but the collective body language suggests that only CBD will be rescheduled, leaving cannabis as Schedule I. This is due to perceived fear of THC, the cannabinoid that is responsible for the euphoria often associated with cannabis, and widely considered the black sheep of the cannabinoid family.
We believe that perception is misplaced and GW has two opportunities to establish that. Sativex®, a THC-based oromucosal spray for the treatment of MS spasticity, has already received regulatory approval in numerous countries outside the U.S., and we expect an NDA to be filed shortly. Further along the clinical pathway, and the story to which nobody seems to be paying attention to, is glioblastoma, or brain cancer, which we believe will serve as the foundation of GW’s oncology platform and demonstrate once-and-for-all the efficacious agility of cannabinoid wellness. In February of 2017, GW announced positive phase two primary endpoints for their GBM trial, which used a 1:1 CBD:THC ratio, but they couldn’t release secondary endpoints (overall survival) because “too many people were still surviving.” CEO Justin Gover said at the time that more information would likely be available in “the coming weeks to months.” Fast-forward to August 2018, a full seventeen months later, and we’re still waiting for those secondary endpoints. The only data we received, a few weeks ago, was that the median survival rate was 662 days compared to 369 days on placebo, and that the company received an Orphan Drug Designation from both the FDA and EMA.